Peter G M Mol (Peter Mol)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 34

Top Venues

Drug safety

Clinical pharmacology and therapeutics

Journal of market access & health policy

British journal of clinical pharmacology

Medicines Evaluation Board

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Medicines Evaluation Board Mar 01 2003

Netherlands

principal assessor

University Medical Center Groningen Feb 01 2001

Netherlands

Assistant Professor :: Clinical Pharmacy and Pharmacology

Publications

Francine Brinkhuis, Elaine Julian, Hendrika van den Ham, Fabrizio Gianfrate, Valentina Strammiello, Michael Berntgen, Mira Pavlovic, Peter G M Mol, Jürgen Wasem, Walter Van Dyck, Antonella Cardone, Christian Dierks, Anja Schiel, Renato Bernardini, Oriol Solà-Morales, Jörg Ruof, Wim Goettsch
Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy. Health research policy and systems 22 (1) (2024)
Anna Maria Gerdina Pasmooij, Peter G M Mol, Jacob Cornelis Bot, Hubertus G Leufkens
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report. Clinical pharmacology and therapeutics 116 (1) (2024)
Francine Brinkhuis, Elaine Julian, Hendrika van den Ham, Fabrizio Gianfrate, Valentina Strammiello, Michael Berntgen, Mira Pavlovic, Peter G M Mol, Jürgen Wasem, Walter Van Dyck, Antonella Cardone, Christian Dierks, Anja Schiel, Renato Bernardini, Oriol Solà-Morales, Jörg Ruof, Wim Goettsch
Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy. Health research policy and systems 22 (1) (2024)
Anna Maria Gerdina Pasmooij, Peter G M Mol, Jacob Cornelis Bot, Hubertus G Leufkens
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report. Clinical pharmacology and therapeutics 116 (1) (2024)
Stefanie Prilla, Sophie Groeneveld, Alexandra C Pacurariu, María Clara Restrepo-Méndez, Patrice Verpillat, Carla Torre, Christian Gartner, Peter G M Mol, Frauke Naumann-Winter, Kieran C Breen, Nathalie Gault, Liana Gross-Martirosyan, Sylvie Benchetrit, Brian Aylward, Violeta Stoyanova-Beninska, Maura O'Donovan, Sabine Straus, Jesper Kjaer, Peter Arlett
Real-World Evidence to Support EU Regulatory Decision Making-Results From a Pilot of Regulatory Use Cases. Clinical pharmacology and therapeutics (2024)
Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven R A Simoens, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter G M Mol, Anja Schiel, Wim G Goettsch, Hendrika van den Ham, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Jörg Ruof
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators. Journal of market access & health policy 12 (1) (2024)
Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven R A Simoens, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter G M Mol, Anja Schiel, Wim G Goettsch, Hendrika van den Ham, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Jörg Ruof
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators. Journal of market access & health policy 12 (1) (2024)
Anna Maria Gerdina Pasmooij, Peter G M Mol, Jacob Cornelis Bot, Hubertus G Leufkens
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report. Clinical pharmacology and therapeutics (2024)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Guiling Zhou, Stijn de Vos, Catharina C M Schuiling-Veninga, Jens H J Bos, Katrien Oude Rengerink, Anna Maria Gerdina Pasmooij, Peter G M Mol, Geertruida H de Bock, Eelko Hak
Community Use of Repurposed Drugs Before and During COVID-19 Pandemic in the Netherlands: An Interrupted Time-Series Analysis. Clinical epidemiology 15 (2023)
Sieta T de Vries, Noral Huda S Al-Mugoter, Irena Petkoska, Stefan Verweij, André J A Elferink, Peter G M Mol
Comment on: "The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022". Applied health economics and health policy (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Esther de Vries, Elisabeth Bakker, Reynold D C Francisca, Stijn Croonen, Petra Denig, Peter G M Mol
Handling of New Drug Safety Information in the Dutch Hospital Setting: A Mixed Methods Approach. Drug safety 45 (4) (2022)
Marko J Kallio, Viktoriia Starokozhko, Eleonora Agricola, Manja Burggraf, Anne Heß, Wolfgang Ballensiefen, Wiebke Löbker, Yoana Nuevo, Anna Maria Gerdina Pasmooij, Peter G M Mol, null null
Translating Academic Drug Discovery Into Clinical Development: A Survey of the Awareness of Regulatory Support and Requirements Among Stakeholders in Europe. Clinical pharmacology and therapeutics (2022)
Elaine Julian, Hendrika van den Ham, Oriol Solà-Morales, Peter G M Mol, Jean-François Bergmann, Tomas Salmonson, Ansgar Hebborn, Mathilde Grande, Jörg Ruof
How can a joint European health technology assessment provide an 'additional benefit' over the current standard of national assessments? : Insights generated from a multi-stakeholder survey in hematology/oncology. Health economics review 12 (1) (2022)
Esther de Vries, Elisabeth Bakker, Taco B M Monster, Petra Denig, Peter G M Mol
Factors Influencing Preferences and Responses Towards Drug Safety Communications: A Conjoint Experiment Among Hospital-Based Healthcare Professionals in the Netherlands. Drug safety 45 (11) (2022)
Elisabeth Bakker, Kelly Plueschke, Carla J Jonker, Xavier Kurz, Viktoriia Starokozhko, Peter G M Mol
Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making. Clinical pharmacology and therapeutics (2022)
Katerina M Mantila, Anna Maria Gerdina Pasmooij, Christine Erikstrup Hallgreen, Peter G M Mol, Job Frank Martien van Boven
Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross-Sectional Analysis of Centralized Procedures in the European Union 2010-2020. Clinical pharmacology and therapeutics 112 (5) (2022)
Sieta T de Vries, Viktoriia Starokozhko, Ingrid M M Schellens, Leonoor Wijnans, Harald Enzmann, Marco Cavaleri, Peter G M Mol
Attention for sex in COVID-19 trials: a review of regulatory dossiers. BMJ global health 7 (3) (2022)
Esther de Vries, Petra Denig, Sieta T de Vries, Taco B M Monster, Jacqueline Geertruida Hugtenburg, Peter G M Mol
Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands. Drug safety 43 (7) (2021)
Sieta T de Vries, Petra Denig, Corine Ekhart, Peter G M Mol, Eugene P van Puijenbroek
Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study. Drug safety 43 (5) (2021)
Carla J Jonker, Sieta T de Vries, H Marijke van den Berg, Patricia McGettigan, Arno W Hoes, Peter G M Mol
Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders. Drug safety 44 (8) (2021)
Sieta T de Vries, Petra Denig, Adriana Andrić, Marina Dimov Di Giusti, Alicia Ptaszynska-Neophytou, Linda Härmark, Peter G M Mol, null null
Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK. Drug safety 44 (10) (2021)
Sieta T de Vries, Judy Harrison, Patrick Revelle, Alicia Ptaszynska-Neophytou, Anna Radecka, Gowthamei Ragunathan, Phil Tregunno, Petra Denig, Peter G M Mol
Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study. Drug safety 42 (7) (2020)
Carla J Jonker, Katrien Oude Rengerink, Arno W Hoes, Peter G M Mol, H Marijke van den Berg
Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry-based study. Haemophilia : the official journal of the World Federation of Hemophilia 26 (5) (2020)
Petra Denig, Eugene P van Puijenbroek, Nashwa Soliman, Peter G M Mol, Sieta T de Vries
Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care. Pharmacoepidemiology and drug safety 28 (9) (2019)
Sieta T de Vries, Petra Denig, Corine Ekhart, Jako S Burgers, Nanne Kleefstra, Peter G M Mol, Eugene P van Puijenbroek
Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. British journal of clinical pharmacology 85 (7) (2019)
Peter G M Mol, Aliza Thompson, Hiddo J Lambers Heerspink, Hubert G M Leufkens
Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations. Diabetes, obesity & metabolism (2019)
Derbew Fikadu Berhe, Katka Taxis, Flora M Haaijer-Ruskamp, Peter G M Mol
Healthcare professionals' level of medication knowledge in Africa: a systematic review. British journal of clinical pharmacology 84 (12) (2018)

Peter G M Mol.css-eqlu8i{font-size:small;padding-left:4px;} (Peter Mol)

Publication Activity (10 Years)

Top Topics

Top Venues

Peter G M Mol (Peter Mol)